Display options
Share it on

AIDS Res Ther. 2013 Mar 28;10(1):9. doi: 10.1186/1742-6405-10-9.

Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model.

AIDS research and therapy

Edward R Cachay, Lucas Hill, Craig Ballard, Bradford Colwell, Francesca Torriani, David Wyles, William C Mathews

Affiliations

  1. Department of Medicine, Owen Clinic, University of California at San Diego, 200 W, Arbor Drive, San Diego, CA, 92103-8681, USA. [email protected].

PMID: 23537147 PMCID: PMC3620560 DOI: 10.1186/1742-6405-10-9

Abstract

BACKGROUND: Access to Hepatitis C (HCV) care is low among HIV-infected individuals, highlighting the need for new models to deliver care for this population.

METHODS: Retrospective cohort analysis that compared the number of HIV patients who initiated HCV therapy: hepatology (2005-2008) vs. HIV primary care model (2008-2011). Logistic-regression modeling was used to ascertain factors associated with HCV therapy initiation and achievement of sustained viral response (SVR).

RESULTS: Of 196 and 163 patients that were enrolled in the HIV primary care and hepatology models, 48 and 26 were treated for HCV, respectively (p = 0.043). The HIV/HCV-patient referral rate did not differ during the two study periods (0.10 vs. 0.12/patient-yr, p = 0.18). In unadjusted analysis, predictors (p < 0.05) of HCV treatment initiation included referral to the HIV primary care model (OR: 1.7), a CD4+ count ≥400/mm3 (OR: 1.8) and alanine aminotranferase level ≥63U/L (OR: 1.9). Prior psychiatric medication use correlated negatively with HCV treatment initiation (OR: 0.6, p = 0.045). In adjusted analysis the strongest predictor of HCV treatment initiation was CD4+ count (≥400/mm3, OR: 2.1, p = 0.01). There was no significant difference in either clinic model (primary care vs. hepatology) in the rates of treatment discontinuation due to adverse events (29% vs. 16%), loss to follow-up (8 vs. 8%), or HCV SVR (44 vs. 35%).

CONCLUSIONS: Using a HIV primary care model increased the number of HIV patients who initiate HCV therapy with comparable outcomes to a hepatology model.

References

  1. Liver Int. 2012 Sep;32(8):1194-9 - PubMed
  2. AIDS. 2005 Oct;19 Suppl 3:S99-105 - PubMed
  3. AIDS Res Ther. 2011 Aug 10;8:29 - PubMed
  4. AIDS Care. 2012;24(4):434-43 - PubMed
  5. J Gen Intern Med. 2004 Apr;19(4):357-65 - PubMed
  6. Soc Sci Med. 2012 Jul;75(1):240-7 - PubMed
  7. J Viral Hepat. 2011 May;18(5):316-24 - PubMed
  8. Gen Hosp Psychiatry. 2005 Nov-Dec;27(6):431-8 - PubMed
  9. Antivir Ther. 2012;17(3):571-5 - PubMed
  10. J Addict Med. 2010 Dec;4(4):223-32 - PubMed
  11. Subst Use Misuse. 2012 Jan;47(1):56-66 - PubMed
  12. Nature. 2009 Sep 17;461(7262):399-401 - PubMed
  13. Int J STD AIDS. 2011 Oct;22(10):571-6 - PubMed
  14. Clin Infect Dis. 2012 May;54(10):1465-72 - PubMed
  15. Hepatology. 2012 Nov;56(5):1651-60 - PubMed
  16. N Engl J Med. 2009 Apr 30;360(18):1827-38 - PubMed
  17. Lancet. 2011 Apr 2;377(9772):1198-209 - PubMed
  18. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S349-54 - PubMed
  19. AIDS Patient Care STDS. 2009 Nov;23(11):925-9 - PubMed
  20. BMJ. 2012 Feb 20;344:e1266 - PubMed
  21. N Engl J Med. 2011 Mar 31;364(13):1195-206 - PubMed
  22. Hepatology. 2009 Apr;49(4):1335-74 - PubMed
  23. Open Med. 2011;5(3):e120-31 - PubMed
  24. Qual Health Res. 2012 Jan;22(1):54-66 - PubMed
  25. Aust J Prim Health. 2011;17(3):282-7 - PubMed
  26. Addiction. 2002 Sep;97(9):1183-94 - PubMed
  27. AIDS Patient Care STDS. 2012 Sep;26(9):541-5 - PubMed
  28. Antivir Ther. 2011;16(6):815-24 - PubMed

Publication Types